Rxfiles trial summary averroes biography

Presented as apixaban vs.

Rxfiles trial summary averroes biography: RxFiles Trial Summary – RELY:

Statistics presented where given by the authors. Analyses are to time of first event. From Wiki Journal Club. Connolly SJ, et al. The New England Journal of Medicine. Final results.

Rxfiles trial summary averroes biography: Also rivaroxaban was shown to be

Categories : Usable articles Cardiology Neurology. Navigation menu Personal tools Create account Log in. Namespaces Page Discussion. There were 51 primary outcome events in those randomised to apixaban 1. Mortality rates were 3. There were 44 1. There were 11 intracranial bleeds on apixaban and 13 on aspirin apixaban 1. Thus, a clear superiority of apixaban over aspirin was shown in terms of efficacy, with comparable safety.

We will here briefly discuss the clinical implications of the trial. In such patients, aspirin plus clopidogrel reduced the rate of major vascular events, in particular stroke, vs. AVERROES on the other hand has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. Based on the indirect comparison with ACTIVE A, one should conclude that apixaban is, at the time of writing, the best alternative to aspirin ever found in patients deemed unsuitable for VKAs.

Rxfiles trial summary averroes biography: Advantages: non-inferior for stroke

Patients were eligible if they were 50 years of age or older and if they had atrial fibrillation that had been documented in the 6 months prior to enrollment or by lead electrocardiography on the day of screening. In addition, patients could not be receiving VKA therapy, either because it had been demonstrated unsuitable in their case or because it was expected to be unsuitable.

The reasons that VKA therapy was unsuitable for the patient had to be documented in the study case report forms. Of the patients enrolled, reasons for being deemed unsuitable for VKA therapy included the following: 1. Adverse event not related to bleeding during VKA therapy; 3. A serious bleeding event during VKA therapy; 4.

Rxfiles trial summary averroes biography: AVERROES trial, the rate of

Assessment that INR could not or was unlikely to be measured at requested interval; 5. Expected difficulty in contacting patient for urgent change in dose of VKAs; 6. Concurrent medications that could alter activity of VKAs; 8. Concurrent medications whose metabolism could be affected by VKAs; 9. Assessment that patient would be unable or unlikely to adhere to restrictions on factors such as alcohol and diet; Hepatic disease; VKA therapy not recommended by the physician; Other characteristics indicating risk of stroke too low to warrant treatment with VKAs; In these patients, apixaban is a therapeutic option more effective than aspirin, and as safe as aspirin, with a very low rate of major bleeding complications and of intracranial hemorrhage especially.

The study is due to be completed soon. Apixaban in Patients with Atrial Fibrillation. N Engl J Med Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med ;